Novo Nordisk reported results from its phase 3 clinical trial for its experimental obesity drug cagrilintide which showed significant weight loss among participants.
The research, presented at the 2025 European Association for the Study of Diabetes congress in Vienna, found that participants receiving once-weekly monotherapy injections of 2.4 mg cagrilintide, an amylin analogue, lost an average of 11.8% of body weight over 68 weeks, compared to 2.3% in the placebo group.
About 31.6% of those taking the drug lost at least 15% of their body weight, in comparison to 4.7% with the placebo, according to a Sept. 16 news release from the drugmaker.
The most common side effects included gastrointestinal issues such as nausea, vomiting, diarrhea and constipation. Novo Nordisk plans to begin a new phase 3 program later this year to further study the drug in people with obesity.
